Kornimate/medical-research-clean huggingface dataset:
study evaluating the efficacy and safety with cd19car-t for relapsed or refractory non-hodgkin lymphoma

Conditions: Relapsed Non-Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma

Summary: this study is a single-arm, open label, phase i clinical trial to evaluate the safety and feasibility of cd19car-t in treatment of relapsed / refractory non-hodgkin lymphoma


Eligibility criteria:
inclusion criteria: 1. diagnosis with relapsed or refractory non hodgkin lymphoma with cd19 positive 2. age 18 to 65 years old, both male and female; 3. is expected to survive more than 12 weeks; 4. physical condition is good: 0-1 score ecog score; 5. no obvious abnormal heart, liver, kidney, no large wounds that haven't healed on the body; 6. into groups to participate in voluntarily, good adherence, can cooperate test observation, childbearing age women must be 7 days before starting treatment expert pregnancy test and the results were negative, and signed a written informed consent form. exclusion criteria: 1. organ failure, such as heart: class iii and iv; liver: to child grading of liver function grade c; kidney: kidney failure and uremia stage; lung: symptoms of severe respiratory failure; brain: disorder of consciousness; 2. existing serious acute infection, uncontrollable, or have fester sex and chronic infection, wound in delay no more; 3. pregnancy and lactation women; 4. patients who have participated in other clinical trials or other clinical trials in the past 30 days; 5. the investigator believe the patients should not participate in this experiment.
non-immune related hypothyroidism in iodine sufficient area

Conditions: Hypothyroidism

Summary: background: autoimmune hypothyroidism has been regarded as the most common cause of primary hypothyroidism in iodine sufficient area and has relationship with excess iodine induced hypothyroidism. however, non-immune related hypothyroidism and its relationship with excess iodine have been rarely evaluated. objective: therefore, the investigators planned to calculate proportion of non-immune related hypothyroidism and relationship with iodine intake using nationwide data from korea national health and nutrition examination survey (knhanes) 2013-2015. design: 1. korea national health and nutrition examination survey vi (2013 to 2015) - the national data - which is the government designated statistics (approval no. 117002 ) of south korea based on the article 17 of the national health promotion act - were used. the survey was approved by the institutional review board of the korea centers for disease control and prevention, and provides only non-identified measures for academic research purposes. 2. the participants who were examined for thyroid stimulating hormone, free thyroxine, thyroid peroxidase antibody (tpo ab), and urine iodine concentration (uic) were included. 3. the proportion of immune related and non-immune related hypothyroidism was evaluated. demographic variables and severity of hypothyroidism were compared between the two groups. to analyze iodine effect on hypothyroidism in tpo ab positive or negative population, prevalence of hypothyroidism were assessed in each tpo ab negative and positive population according to uic subgroups. 4. this study protocol was approved by irb of smc (2017-05-149).


Eligibility criteria:
inclusion criteria: * examined for thyroid stimulating hormone, free thyroxine, thyroid peroxidase antibody (tpo ab), and urine iodine concentration (uic) exclusion criteria: * already have a thyroid disease(benign thyroid diseases or thyroid cancer).

Keywords: iodine thyroid peroxidase antibody
methylprednisolone before fludeoxyglucose-labeled positron emission tomography in patients with lung cancer

Conditions: Lung Cancer

Summary: the purpose of this study is to determine whether giving an anti-inflammatory medication (corticosteroid) prior to a positron emission tomography scan (pet) scan may reduce or eliminate false findings related to inflammation

primary objectives: i. to assess whether premedication with a corticosteroid may reduce false positive findings on fluorodeoxyglucose (fludeoxyglucose f 18 \[fdg\[) pet/computed tomography (ct) scans in lung cancer patients, by reducing radiotracer uptake in thoracic lymph nodes related to inflammation. outline: within 1-14 days of undergoing standard fdg pet/ct scan, patients receive methylprednisolone intravenously (iv) and then undergo a second fdg pet/ct scan. after completion of study treatment, patients are followed up for 2 years.

Eligibility criteria:
inclusion criteria: * patient undergoing initial staging of biopsy proven lung cancer (all cancer stages included) * undergone clinical fdg pet/ct scan within 14 days of enrollment exclusion criteria: * prisoners * diabetic patients (on insulin, on oral hypoglycemic, or fasting glucose \> 180 mg/dl) * serious infection within 14 days of enrollment * known hypersensitivity to methylprednisolone * viral skin lesions * immunocompromised anc(absolute neutrophil count \< 1000/microliter) * pregnant/nursing * history of tuberculosis or systemic fungal disease * history of steroid psychosis * current peptic ulcer disease or diverticulitis * corticosteroid use within 14 days of enrollment (including inhaled steroids)
pulse radiofrequency and occipital nerve block for chronic migraine patients

Conditions: Chronic Migraine, Headache; Block; Occipital Neuralgia

Summary: in this study, the effect of nerve blockade and radiofrequency treatment applied to the nerve on pain in chronic migraine patients will be investigated. occipital nerve blockade group (control group): depending on the location of the pain, blockade will be applied unilaterally or bilaterally with 5 cc of 2% prilocaine for each sıde. pulse radiofrequency application to the greater occipital nerve will be applicated after radiofrequency cannula placed near the greater occipital nerve location with 42 degree, for 240 seconds.

patients between the ages of 18-60 years, who were resistant to medical treatment and diagnosed with chronic migraine according to ichd-3 beta criteria (migraine pain for more than 15 days in the last 3 months) who applied to the neurology and algology outpatient clinic were included in the study. all procedures were performed with the patient in the prone position, using anatomical landmarks in the target areas. for gon blockade, the target point for the greater occipital nerve was identified along a line connecting the external occipital protuberance to the mastoid process (usually 1.5-3 cm lateral to the midline) and one-third of the distance medial to the artery at the level of the superior nuchal process. after local anesthesia with skin-subcutaneous 1% lidocaine, bone contact was obtained using a 25-gauge needle. for pulse radiofrequency, the target point for the greater occipital nerve was determined as one third of the distance medial to the artery along a line connecting the external occipital protuberance to the mastoid process (usually 1.5-3 cm lateral to the midline) and at the level of the superior nuchal process. after local anesthesia with skin-subcutaneous 1% lidocaine, a 5 cm long 20 gauge radiofrequency needle with a 5 mm active tip was inserted close to the targeted nerve. sensory and motor electrical stimulation was performed to elicit a compatible paresthesia response in the occipital distribution. pulsed radiofrequency was applied at 42 degrees c for 240 seconds. patients were observed after the procedure. patients were observed before and after the procedure.

Eligibility criteria:
inclusion criteria: * patients between 18-60 years of age diagnosed with chronic migraine according to ihs criteria exclusion criteria: * pregnancy * major psychiatric disorder * bleeding diathesis * local infection * allergy

Keywords: chronic migraine greater occipital nerve block pulse radio frequency pain management
electroacupuncture for dysmenorrhea secondary to adenomyosis

Conditions: Dysmenorrhea; Adenomyosis; Electroacupuncture

Summary: the aim of this study is to preliminarily evaluate the is to assess the effects and safety of electroacupuncture for moderate to severe dysmenorrhea secondary to adenomyosis.


Eligibility criteria:
inclusion criteria: * meeting the diagnosis criteria of dysmenorrhea secondary to adenomyosis. * female patients aged between 18 and 50. * dysmenorrhea lasting for 3 consecutive menstrual cycles or more. * at least three consecutive menstrual cycles with an interval of 24 to 38 days, differing by less than 7 days, and menstrual periods lasting 2 to 8 days before screening. * at least 2 days of worst pain score ≥4 on numerical rating scale during the screening period. * having not used medications, other than rescue medicine, or therapies for dysmenorrhea secondary to adenomyosis for at least 1 month before randomization, and consenting not to use throughout the process of the research. * volunteering to participate the trial and signing written informed consent. exclusion criteria: * diagnosed with endometriosis or having a history of endometriosis-related surgery * currently taking hormonal medications, including: a.use of gnrh agonists within 6 months before the screening period; b. use of progestins or danazol and other long-acting hormones within 3 months before the screening period; c. use of oral contraceptive-like short-acting hormones within one month before the screening period; * having clinically significant gynecologic condition such as clinically significant endometrial pathology, persistent complex ovarian cyst larger than 3 cm or simple ovarian cyst larger than 5 cm, or single fibroid 4 cm or larger or more than 4 fibroids measuring at least 2 cm or symptomatic submucosal fibroid of any size. * having an iud. * hb \< 90g/l. * having any other chronic pain syndrome that required chronic analgesic or other chronic therapy. * having a current history of undiagnosed abnormal genital bleeding. * malignant tumors (including the reproductive system and other systems). * combined with severe diseases in the cardiac, respiratory, renal, liver, and hematopoietic systems, psychiatric disorder and/or cognitive disorders. * pregnant, breast feeding, planning a pregnancy within the next 7 months.

Keywords: dysmenorrhea adenomyosis electroacupuncture
relevance of [68ga]ga -pentixafor-pet for initial staging and therapeutic evaluation of multiple myeloma

Conditions: Multiple Myeloma

Summary: the aim of our study is to confirm the relevance of pet using \[68ga\]ga -pentixafor ligand, in comparison with fdg, for initial staging and therapeutic evaluation of symptomatic multiple myeloma patients in first line treatment or in relapse. the prognostic value of positive cxcr4 expression will also be assessed and \[68ga\]ga -pentixafor/fdg discordances explored.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * symptomatic mm patients according to imwg criteria (12) requiring first-line treatment * written and signed informed consent (obtained on the screening day at the latest and before any investigation) * ecog (eastern cooperative oncology group) \< 2 * patient affiliated to or beneficiary of the national health service exclusion criteria: * hiv positive, active hepatitis b or c * childbearing or child breast feeding women * women or men without effective contraceptive barrier if needed * egfr \< 50 ml/min by mdrd or ckdepi * previous or concurrent second malignancy except for adequately treated basal cell carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively treated solid cancer, with no evidence of disease for at least 2 years * any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * known active infection * patient with uncontrolled insulin-dependent or non-insulin-dependent diabetes mellitus * patient under guardianship or trusteeship * patient under judicial protection
evaluation of a self-management oriented diabetes education program for intensified insulin therapy in type 2 diabetes

Conditions: Type 2 Diabetes

Summary: a new diabetes education program for the initiation of intensive insulin therapy in type 2 diabetic patients (medias 2 ict) was developed. in the evaluation, this new developed program is compared with an education programs which is currently used for diabetes education. it is expected that the new developed program (medias 2 ict) can demonstrate non-inferiority with regard to the main outcome variable glycemic control. if non-inferiority can be demonstrated superiority of this programs will be tested. the results regarding the intervention arms "medias ict" vs. " acc" (control condition) will be separately analyzed and published.

the medias 2 ict program is based on a self-management/empowerment approach. it is conducted as a group program comprising 10 lessons of 90 minutes each. medias 2 ict is designed to help patients perform multiple-injection insulin therapy and adjust their insulin doses depending on carbohydrate consumption, physical exercise, and pre-prandial glucose levels. in addition, medias 2 ict focuses on controlling metabolic risk factors (elevated lipids and blood pressure), coping with the risk of late complications, and reducing the emotional burden of diabetes and its treatment. the active comparator condition (acc) consist of a combination of two previously established and evaluated education programs - a diabetes education program to initiate mealtime insulin and a hypertension education program for the treatment of hypertension. these education programs were developed in the 1980s and 1990s and were more didactic-oriented, focusing primarily on the acquisition of knowledge, skills, and information about the correct treatment of diabetes and hypertension. both treatment arms (medias 2 ict and acc) consisted of 10 lessons, which were conducted as group sessions.

Eligibility criteria:
inclusion criteria: * type 2 diabetes * age \ 17 years * two years diabetes duration with oral treatment * bmi \> 20 nad bmi \< 40 kg/m² * informed consent exclusion criteria: * current psychiatric disease * dementia or other severe cognitive impairment * severe complications * severe conditions (e.g., cancer) * gestational diabetes

Keywords: type 2 diabetes education self-management insulin therapy
fucoidan improves the metabolic profiles of patients with non-alcoholic fatty liver disease (nafld)

Conditions: Non-alcoholic Fatty Liver Disease

Summary: studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis. the subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral fucohiq capsules.

fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness. the strongest fucoidan among all seaweed for inhibiting cancer cells is in okinawa japanese waters. for chemically speaking, the major components for fucoidan consisted of mainly fucose which is a kind of polysaccharide with strong biological activity. however, patients need to take actual fucoidan in order to reach the best effectiveness for inhibiting cancer cell. studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis. the subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral fucohiq capsules.

Eligibility criteria:
inclusion criteria: * patients who are aged between 20-75 with non alcoholic fatty liver disease (nafld). exclusion criteria: 1. patients were allergic to seafood. 2. patients who take vitamin e or pioglitazone.
regisry of the stroke patients in assiut university hospital

Conditions: All Patients With Ischemic Cerebrovascular Stroke Aged ≥18 Years of Both Sex

Summary: • aim of the work to register all type of acute stroke admitted in assiut university hospital and assessment of their risk factor, morbidity and mortality


Eligibility criteria:
inclusion criteria: * all patients with stroke aged ≥18 years of both sex * written consent was taken for all patient either from the patient himself of closes relative after explaning to them the type of treatment benefits and possible risks exclusion criteria: * stroke due to metabolic causes as hypoglycemia liver, renal failure and other metabolic causes * stroke due to brain tumors
early identification of cardiac involvement in patients with carcinoid: clinical and prognostic implications

Conditions: Neuroendocrine Tumors

Summary: this study is for patients with neuroendocrine tumours (net) with or without carcinoid syndrome followed by net unit of european institute of oncology. the objective of the trial is to evaluate biochemical markers of myocardial injury (high-sensitive troponins), haemodyinamic markers (pro-brain natriuretic peptide (bnp), n-terminal (nt)-bnp (nt-probnp)), and markers of fibrosis (suppression of tumorigenicity 2 (st2) in patients with neuroendocrine tumours (net) with or without carcinoid syndrome.

the main aim of this study is to evaluate blood levels of biomarkers of cardiac damage (ultra-sensitive troponin i), hemodynamic impairment (bnp, nt-probnp), and cardiac fibrosis (st2) in patients with diagnosed neuroendocrine tumours (net) with or without carcinoid syndrome the secondary objective is to correlate the levels of the above markers with the presence/entity of cardiac involvement and its progression over time. all patients will undergo: * a baseline assessment including: * blood sampling for us-troponin i, bnp, nt-probnp, st2 * cardiological evaluation including ecg and echocardiogram * a three-monthly revaluation of these markers * a six monthly cardiological reassessment with a echocardiogram

Eligibility criteria:
inclusion criteria: * patients diagnosed with metastatic net with or without carcinoid referred to the unit of neuroendocrine tumors of european institute of oncology exclusion criteria: * age \<18 years * patients diagnosed with heart disease prior to diagnosis of net
pulsating electromagnetive treatment (pemf) at treatment resistant depression

Conditions: Treatment Resistant Depression

Summary: in this study patients with treatment resistant depression, as defined by harold sackeim, is subjected to daily sessions, for eight weeks, with pulsating electromagnetive treatment (pemf). treatment is given two times a day, in the morning and in the afternoon. patients are randomized into two groups. in group a patients receive active treatment both morning and afternoon. in group b patients receive one sham and one active treatment. the study is double-blind as neither the assessors or patients are aware of treatment allocation. each session lasts 30 minutes. patients are psychometrically assessed weekly for depression severity and side effect. after this intervention period patients are followed for further three weeks without pemf treatment. patients are on unchanged medication for the whole of the study period.


Eligibility criteria:
inclusion criteria: * treatment resistant major depression (grade 3 sackeim criteria) * age above 18 and below 85 * hamilton (17 item version) score above 12 * unchanged psychopharmacological treatment for last five weeks. exclusion criteria: * suicidality above 2 on item three on hamilton scale or,earlier pemf treatment * dementia or similar cognitive impairment * psychotic disorder * abuse of alcohol or drugs * pregnant or lactating women * insufficient birth control measures

Keywords: randomized controlled trial major depression hamilton pemf
outcome of patients with cbf and/or npm1-mutated aml in first molecular relapse.

Conditions: Acute Myeloid Leukemia

Summary: despite good initial response, some patients with core binding factor and/or npm1-mutated aml eventually relapse. some of these patients can be identified earlier on, before overt cytological relapse, when followed for minimal residual disease. the outcome of patients treated when molecular relapse is confirmed, before overt cytological relapse, is not well known. this multi-center retrospective will therefore study the outcome of these patients and try to specify the role of allogeneic stem cell transplantation in this setting.


Eligibility criteria:
inclusion criteria: * patients between 18 and 61 years * diagnosis between 2010 and 2019 * core binding factor and/or npm1 acute myeloid leukemia * first complete remission after induction therapy * measurable residual disease measurement after end of consolidation therapy exclusion criteria: * acute promyelocytic leukemia * allogeneic stem cell transplantation in cr1
the effect of using 70% ethanol alcohol as a root canal irrigant on increasing the success rate of metapex in pulpectomy compared to normal saline in primary molars

Conditions: Pulpitis - Irreversible; Resorption, Root; Abscess Bone; Mobility, Tooth; Pain

Summary: the aim of the study is to perform a clinical and radiographic evaluation of 70% ethanol alcohol versus normal saline as root canal irrigating solutions in partial pulpectomy of primary molars with metapex.

in permanent dentition, calcium hydroxide-iodoform paste (metapex) has a high potential in forming a calcific barrier in the pulpal tissue. yet, in primary dentition metapex forms a chronic inflammatory reaction to the pulpal tissue leading to its internal and root resorption. although the high success rate of metapex in partial pulpectomy, the rapid resorption of metapex has led to the presence of the hollow tube effect due to voids formation in the canals. however, this will cause early root resorption before the time of exfoliation. due to its rapid resorption, metapex is usually recommended to be used in the pulpectomy of teeth near exfoliation in order to avoid the early root resorption of primary dentition in order to avoid the premature loss of the endodontically treated vital primary teeth with metapex. saline solution is the basic irrigating solution in root canal treatments, yet it has no antimicrobial activities and only results in cleaning the root canals. ethanol irrigation is believed to be an alternative promising replacement in tissue fixation from formocresol due to the concerns from its carcinogenicity and toxicity. also, ethanol has an excellent bactericidal, virucidal, and fungicidal, and most importantly it is one of the volatile liquids. in this study, the effect of ethanol alcohol on increasing the success rate of metapex in vital pulp therapy will be studied.

Eligibility criteria:
inclusion criteria: 1. patients medically within normal. 2. cooperative patients and cooperative parents. 3. children aged 4-7 years old. 4. primary mandibular second molar. 5. deep carious molars. 6. a history of spontaneous pain. 7. molars with pulp exposure due to caries. 8. absences of internal resorption. 9. absences of external pathological resorption. 10. where the bleeding could not be stopped following removal of the coronal pulp tissue exclusion criteria: 1. parents unable to give informed consent. 2. necrotic pulp. 3. unrestorable teeth.

Keywords: metapex primary dentition